Synthesis and Pharmacokinetics of a Dihydropyridine Chemical Delivery System for the Antiimmunodeficiency Virus Agent Dideoxycytidine

Journal of Medicinal Chemistry

Volumn 36, Issue 5, 1993, Pages 529-537

  Torrence, Paul F ^a   Kinjo, Jun ei ^a   Khamnei, Shahrzad ^a   Greig, Nigel H ^b  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2',3' DIDEOXYCYTIDINE DERIVATIVE; 5',4N BIS(1,4 DIHYDRO 1 METHYLNICOTINOYL) 2',3' DIDEOXYCYTIDINE; UNCLASSIFIED DRUG; ZALCITABINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; DRUG HALF LIFE; DRUG METABOLISM; DRUG THERAPY; DRUG UPTAKE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; OXIDATION REDUCTION REACTION; PHARMACOKINETICS; PRIORITY JOURNAL; RAT;

ANIMAL; BIOTRANSFORMATION; BRAIN; CYTOSINE; CYTOSOL; DIHYDROPYRIDINES; DRUG CARRIERS; HIV; HIV-1; HYDROLYSIS; KINETICS; MALE; OXIDATION-REDUCTION; PRODRUGS; RATS; RATS, WISTAR; SUPPORT, U.S. GOV'T, P.H.S.; ZALCITABINE;

EID: 0027395053     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm00057a002     Document Type: Article

References (28)

1. Tucker, T. Central Nervous System AIDS. J. Neurol. Sci. 1989, 89, 119–132.
2. Budka, H. Human Immunodeficiency Virus (HIV)-Induced Disease of the Central Nervous System: Pathology and Implications for Pathogenesis. Acta Neuropathol. 1989, 77, 225–236.
3. Eilbott, D. J.; Peress, N.; Burger, H.; LaNeve, D.; Orenstein, J.; Gendelman, H.; Seidman, R.; Weiser, B. Human Immunodeficiency Virus Type 1 in Spinal Cords of Acquired Immunodeficiency Syndrome Patients with Myelopathy: Expression and Replication in Macrophages. Proc. Natl. Acad. Sci. U.S.A. 1989, 86, 3337–3341.
4. Price, R. W.; Brew, B.; Sidtis, J.; Rosenblum, M.; Scheck, A. C.; Cleary, P. The Brain in AIDS: Central Nervous System HIV-1 Infection and AIDS Dementia Complex. Science 1988, 239, 586–592.
5. Navia, B. A.; Jordan, B. D.; Price, R. W. The AIDS Dementia Complex: I Clinical Features. Ann. Neurol. 1986, 19, 517–524.
6. Torrence, P. F.; Kinjo, J.; Lesiak, K.; Balzarini, J.; De Clercq, E. AIDS Dementia: Synthesis and Properties of a Derivative of 3′-Azido-3′-Deoxythymidine (AZT) that may become ‘Locked’ in the Central Nervous System. FEBS Lett. 1988, 234, 135–140.
7. Palomino, E.; Kessel, D.; Horwitz, J. P. J. A Dihydropyridine Carrier System for Sustained Delivery of 2′,3′-Dideoxynucleosides to the Brain. J. Med. Chem. 1989, 32, 622–625.
8. Chu, C. K.; Bhadti, V. S.; Doshi, K. J.; Etse, J. T.; Gallo, J. M.; Boudinot, F. D.; Schinazi, R. F. Brain Targeting of Anti-HIV Nucleosides: Synthesis and in Vitro and in Vivo Studies of Dihydropyridine Derivatives of 3′-Azido-2′,3′-Dideoxyuridine and 3′-Azido-3′-Deoxythymidine. J. Med. Chem. 1990, 33, 2188–2192.
9. Gogu, S. R.; Aggarwal, S. K.; Rangan, S. R. S.; Agrawal, K. C. A Prodrug of Zidovudine with Enhanced Efficacy Against Human Immunodeficiency Virus. Biochem. Biophys. Res. Comm. 1989, 160, 656–661.
10. Brewster, M. E.; Anderson, W.; Bodor, N. Brain, Blood, and Cerebrospinal Fluid Distribution of a Zidovudine Chemical Delivery System in Rabbits. J. Pharm. Sci. 1991, 80, 843–846.
11. Aggarwal, S. K.; Gogu, S. R.; Rangan, S. R. S.; Agrawal, K. C. Synthesis and Biological Evaluation of Prodrugs of Zidovudine. J. Med. Chem. 1990, 33, 1505–1510.
12. Klecker, R. W.; Collins, J. M.; Yarchoan, R. C.; Thomas, R.; McAtee, N.; Broder, S.; Myers, C. E. Pharmacokinetics of 2′,3′-Dideoxycytidine in Patients with AIDS and Related Disorders. J. Clin. Pharmacol. 1988, 28, 837–842.
13. Kelley, J. A.; Litterst, C. L.; Roth, J. S.; Vistica, D. T.; Poplack, D. G.; Conney, D. A.; Nadkarni, M.; Balis, F. M.; Broder, S.; Johns, D. G. The Disposition and Metabolism of 2′,3′-Dideoxycytidine, An in Vitro Inhibitor of Human T-Lymphotrophic Virus Type III Infectivity, in Mice and Monkeys. Drug Metab. Dispos. 1987, 15, 596–601.
14. Tomaszewski, J. E.; Grieshaber, C. K.; Baizarini, J.; Johns, D. G.; Smith, A. C.; Liao, J. T.; Collins, W. T., Jr. Toxicologic and Pharmacokinetic Evaluation of 2′,3′ Dideoxycytidine (ddCyd, NSC-606170), A Potential Drug to treat AIDS. Proc. Am. Assoc. Cancer Res. 1987, 28, 440.
15. Collins, J. M.; Klecker, R. W.; Kelley, J. A.; Roth, J. S.; McCully, C. L.; Balis, F.; Poplack, D. G. Pyrimidine Dideoxyribonucleosides: Selectivity of Penetration into Cerebrospinal Fluid. J. Pharmacol. Exp. Ther. 1988, 245, 466–470.
16. Bodor, N.; Brewster, M. E. Problems of Delivery of Drugs to the Brain. Pharmacol. Ther. 1983, 19, 337–396.
17. Bodor, N. Targeting of Drugs to the Brain. Methods Enzymol. 1985, 112, 381–396.
18. Bodor, N.; Nakamura, T.; Brewster, M. E. Improved Delivery Through Biological Membranes. Synthesis, Distribution, and Neurochemical Effects of a Tryptamine Chemical Delivery System. Drug Des. Deliv. 1986, 1, 51–64.
19. Brewster, M. E.; Estes, K. S.; Bodor, N. Improved Delivery Through Biological Membranes. 32. Synthesis and Biological Activity of Brain-Targeted Delivery Systems for Various Estradiol Derivatives. J. Med. Chem. 1988, 31, 244–249.
20. Wu, W.; Pop, E.; Shek, E.; Bodor, N. Brain-Specific Chemical Delivery Systems for β-Lactam Antibiotics. In Vitro and in Vivo Studies of Some Dihydropyridine and Dihydroisoquinoline Derivatives of Benzylpenicillin in Rats. J. Med. Chem. 1989, 32, 1782–1788.
21. Pop, E.; Wu, W.; Shek, E.; Bodor, N. Brain-Specific Chemical Delivery Systems for β-Lactam Antibiotics. Synthesis and Properties of Some Dihydropyridine and Dihydroisoquinoline Derivatives of Benzypenicillin. J. Med. Chem. 1989, 32, 1774–1781.
22. Sun, L.; Singer, B. Reaction of Cytidine with Ethylating Agent Biochemistry 1974, 13, 1905–1913.
23. Ibrahim, S. S.; Boudinot, F. D. Pharmacokinetics of 2′,3′-Dideoxycytidine in Rats: Application to Interspecies. J. Pharm. Pharmacol. 1989, 41, 829–834.
24. Sarret, H. P.; Perlzweig, W. A.; Levy, E. D. Synthesis and Excretion of Trigonelline. J. Biol. Chem. 1940, 135, 483–485.
25. Buddy, A. V.; Zhang, K.; LePage, F.; Tombret, F.; Slatter, J. A.; Baillie, T. A.; Levy, R. H. In Vitro and in Vivo Investigation of Dihydropyridine-Based Chemical Delivery Systems for Anticonvulsants. Pharm. Res. 1991, 8, 690–697.
26. Mitsuya, H.; Weinhold, J. K.; Furman, A. P.; Clair, ST. M.; Lehman, S.; Gallo, C. R.; Bolognesi, D.; Barry, W. D.; Broder, S. 3′-Azido-3′-Deoxythymidine (BW A509U): An Antiviral Agent that Inhibits the Infectivity and Cytopathic Effect of Human T-Lymphotropic Virus Type III/Lymphadenopathy-Associated Virus in Vitro. Proc. Natl. Acad. Sci. U.S.A. 1985, 82, 7096–7100.
27. Yarchoan, R.; Perno, C. F.; Thomas, R. V.; Klecker, R. W.; Allain, J. P.; Wills, R. J.; McAtee, N.; Fischl, M. A.; Dubinsky, R.; McNeely, M. C.; Mitsuya, H.; Pluda, J. M.; Lawley, T. J.; Leuther, M.; Safai, B.; Collins, J. M.; Myers, C. E.; Broder, S. Phase I Studies of 2′,3′-Dideoxycytidine in Sever Human Immunodeficiency Virus Infection as a Single Agent and Altering with Zidovudine (AZT). Lancet 1988, 1, 76–81.
28. Ohno, K.; Pettigrew, K. D.; Rapaport, S. I. Lower Limits of Cerebrovascular Permeability to Nonelectrolytes in the Conscious Rat. Am. J. Physiol. 1979, 235, H299–H307.